Vector-borne diseases (VBDs) represent a significant public health challenge in India, contributing significantly to the country's disease burden. With a diverse range of vectors and climatic conditions conducive to their spread, understanding the extent of this issue is critical for healthcare professionals.
VBDs in India encompass a wide range of illnesses, including malaria, dengue, chikungunya, Japanese encephalitis, and lymphatic filariasis. Each of these diseases presents unique challenges in terms of prevention, diagnosis, and treatment, necessitating a comprehensive understanding of their epidemiology and clinical manifestations.
The epidemiology of VBDs in India is complex, influenced by factors like vector ecology, climate, and socio-economic determinants. Malaria alone accounts for a significant proportion of the disease burden, with an estimated 219 million cases globally in 2017, of which India contributed 4%. Additionally, the country reports the highest dengue burden in the world, with an estimated 100 million cases annually.
The management of VBDs in India faces numerous challenges, including inadequate surveillance, limited resources for vector control, and gaps in public awareness. However, opportunities exist in the form of advancements in diagnostic technologies, vaccine development, and integrated vector management strategies. The role of healthcare professionals is pivotal in leveraging these opportunities to mitigate the VBD burden.
Vector-borne diseases pose a significant public health challenge in India, requiring a comprehensive, multi-faceted approach. Healthcare professionals play a crucial role in this endeavor, from enhancing disease surveillance and diagnosis to driving public education efforts. By deepening our understanding of these diseases and their management, we can work towards reducing their impact on India's health landscape.
1.
Discovery reveals protein involved in Parkinson's disease also drives skin cancer
2.
The prognosis of the Slovakian PM; Kate Middleton's treatment; and drug test cheating.
3.
We Don't Always Know What's 'Best' for Our Patients
4.
New tumor therapy approach reduces costs and side effects while increasing accessibility
5.
Dual-action mRNA vaccine takes aim at aggressive skin cancer
1.
The Evolving Arsenal: A 2025 Review of Antibody-Drug Conjugates and the Future of Precision Oncology
2.
Case Study: Combining Targeted Therapy with Immunotherapy for Metastatic Melanoma
3.
Anion Gap: The Simple Calculation That Reveals Much About Your Health
4.
Contemporary Methods in Hematology Across Clinical Settings
5.
Unlocking the Potential of Cytarabine: A New Era of Cancer Treatment
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
2.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VI
3.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Further Talks
4.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option
5.
Current Scenario of Cancer- Palliative Care to Close the Care Gap
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation